SJS Investment Consulting’s Sarepta Therapeutics SRPT Stock Holding History

SJS Investment Consulting’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.58K	Sell	255 -230	-47%	-$4.35K	﹤0.01%	1427
2026 Q1	$10.6K	Sell	485 -384	-44%	-$7.43K	﹤0.01%	823
2025 Q4	$18.7K	Buy	869 +603	+227%	+$12.7K	﹤0.01%	650
2025 Q3	$5.13K	Sell	266 -200	-43%	-$3.56K	﹤0.01%	694
2025 Q2	$7.97K	Sell	466 -1	-0.2%	-$43	﹤0.01%	357
2025 Q1	$29.8K	Hold	467	–	–	0.01%	246
2024 Q4	$56.8K	Sell	467 -1	-0.2%	-$123	0.01%	175
2024 Q3	$58.4K	Buy	468 +466	+23,300%	+$64.4K	0.01%	188
2024 Q2	$316	Buy	2 +1	+100%	+$128	﹤0.01%	1425
2024 Q1	$130	Hold	1	–	–	﹤0.01%	1546
2023 Q4	$97	Hold	1	–	–	﹤0.01%	1553
2023 Q3	$122	Hold	1	–	–	﹤0.01%	1520
2023 Q2	$115	Buy	+1	New	+$129	﹤0.01%	1503

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

SJS Investment Consulting's SRPT Position: Q2 2026 in Review

SJS Investment Consulting reduced its Sarepta Therapeutics (SRPT) stake by 47% in Q2 2026, selling an estimated $4.35K and leaving 255 shares worth $4.58K. The position accounts for ﹤0.01% of the portfolio, ranked #1427.

SJS Investment Consulting first reported a position in SRPT in Q2 2023 and has held it in 13 quarters since. The position peaked at $58.4K in Q3 2024. 123 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

SJS Investment Consulting held 255 shares of Sarepta Therapeutics worth $4.58K as of Q2 2026.
SJS Investment Consulting sold 230 Sarepta Therapeutics shares in Q2 2026, an estimated $4.35K.
Sarepta Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1427 holding.
SJS Investment Consulting first reported a position in Sarepta Therapeutics in Q2 2023 and has held it in 13 quarters since.
SJS Investment Consulting's Sarepta Therapeutics position peaked at $58.4K in Q3 2024.
123 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.